Ultrafractionated external radiotherapy in early stage breast cancer. Review of literature and clinical cases.

Abstract

OBJECTIVE: to present the results in our experience Ultrafractionated External Radiotherapy in Early Stage Breast Cancer METHODS: A retrospective review of 30 patients with early stage breast cancer was carried out during the period 2020-2022, the techniques used were Three-dimensional planning technique, and Modulated intensity technique. RESULTS: A total of 30 patients with early stage breast cancer who met the inclusion criteria established for this study, treated with Ultrafractionation (UF) and Hypofractionation (HF) regimens, were analyzed. The average age is 66.9 years, with a range of 44-86 in the (UF) scheme and 64.8 years in the (HF) scheme, with a range of 41-88 years, in the pathological T stage, the majority of the patients were T1c (>10mm <20mm) in (UF) represented by 46.7% of the cases, T1 (<20mm) in (HF) represented by 53.3% the follow-up time is short due to that is being implemented as of 2020, the larger range is represented in 12-24 months (UF) 46.7% and in (HF) 60%. The most frequent acute complications were observed at the skin level: grade I radiodermatitis (UF) 26.7%, in the (HF) group, 13 (86.7%) and 2 patients with grade II radiodermatitis. CONCLUSIONS: Treatment with regimens (UF) has shown to be safe and effective in locoregional control, overall survival, and toxicity.